• Objective overall response rate [ Designated as safety issue: No ]
• Safety [ Designated as safety issue: Yes ]
• Toxicity [ Designated as safety issue: Yes ]

• Objective overall response rate
• Safety
• Toxicity

• Duration of response [ Designated as safety issue: No ]
• Overall survival [ Designated as safety issue: No ]
• Time to progression [ Designated as safety issue: No ]

• Duration of response
• Overall survival
• Time to progression

RATIONALE: Drugs used in chemotherapy, such as BMS-247550, work in different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well BMS-247550 works in treating patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

OBJECTIVES:

• Determine the objective overall response rate of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma treated with BMS-247550.
• Determine the safety and toxicity of this drug in these patients.
• Determine the duration of response, overall survival, and time to progression in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or if the patient becomes a candidate for stem cell transplantation.

Patients are followed every 8 weeks until disease progression.

PROJECTED ACCRUAL: A total of 37-76 patients (22-46 for cohort 1 and 15-30 for cohort 2) will be accrued for this study within 12-18 months.

DISEASE CHARACTERISTICS:

• Histologically confirmed aggressive non-Hodgkin's lymphoma of 1 of the following cellular types:

  • Grade III follicular center
  • Diffuse large B-cell
  • Mantle cell
  • Primary mediastinal B-cell
  • Burkitt's
  • High-grade B-cell (Burkitt-like)

  • Anaplastic large cell of 1 of the following subtypes:

    • CD30-positive
    • T-cell
    • Null cell
    • Hodgkin's-like

• Relapsed or refractory disease after prior standard chemotherapy, meeting criteria for 1 of the following cohorts:

  • Cohort 1 (relapsed but chemosensitive): Prior complete response (CR) or partial response (PR) lasting at least 4 weeks after the most recent prior therapy

  • Cohort 2 (refractory): Stable disease or less than a PR after the most recent prior therapy

    • No progressive disease after the most recent prior therapy

• Measurable disease

  • At least 1 bidimensionally measurable lesion at least 10 mm by conventional techniques or clinical exam

• Ineligible for or unwilling to undergo hematopoietic stem cell transplantation

  • Patients requiring debulking prior to transplant allowed

• No known CNS involvement by lymphoma

  • Prior CNS disease that has been successfully treated in patients with relapsed disease exclusively outside of the CNS may be allowed by the principal investigator

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• More than 3 months

Hematopoietic

• WBC at least 3,000/mm^3
• Absolute neutrophil count at least 1,200/mm^3
• Platelet count at least 100,000/mm^3

Hepatic

• Bilirubin no greater than 1.5 mg/dL
• AST/ALT no greater than 2.5 times upper limit of normal

Renal

• Creatinine no greater than 1.5 mg/dL OR
• Creatinine clearance at least 60 mL/min

Cardiovascular

• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior allergic reaction or hypersensitivity to compounds containing Cremophor EL or agents of similar chemical or biological composition to BMS-247550
• No peripheral neuropathy grade 2 or greater
• No other currently active malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix (previously treated malignancy allowed if considered to be at less than 30% risk of relapse)
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study compliance
• No other concurrent uncontrolled illness

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No colony-stimulating factors (CSFs) within 24 hours of study chemotherapy
• No CSFs during first course of study therapy
• No concurrent filgrastim-SD/01
• No concurrent immunotherapy

Chemotherapy

• See Disease Characteristics
• At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin)
• No other concurrent chemotherapy

Endocrine therapy

• No concurrent hormonal therapy

Radiotherapy

• At least 4 weeks since prior radiotherapy
• No concurrent therapeutic radiotherapy

Surgery

• At least 4 weeks since prior surgery

Other

• Recovered from prior therapy
• At least 7 days since prior cimetidine
• No concurrent cimetidine
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No other concurrent investigational agents
• No other concurrent anticancer medications
• No concurrent unconventional therapies, food, or vitamin supplements containing Hypericum perforatum